{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:12:12Z","timestamp":1783905132449,"version":"3.55.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We retrospectively assessed volumetric response of myxoid liposarcoma (MLPS) with preoperative radiotherapy (RT) and sought to identify disease and treatment characteristics associated with response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We identified all patients with a histologic diagnosis of MLPS who received preoperative RT from 2013 to 2021 at our institution. We used cone beam computed tomography (CBCT) to assess changes in tumor volume and greatest dimension during treatment. Tumors were contoured on CBCT images prior to treatment and at the end of each week of RT. Percentage change in tumor volume and greatest dimension were calculated based on pre-treatment and final week contours. Patients with tumors incompletely visualized on CBCT were excluded from volume analysis but included on greatest dimension analysis. Magnetic resonance imaging (MRI) was used to evaluate pre- and post-RT radiographic features. Surgical pathology was reviewed to record pathologic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients met inclusion criteria. Most tumors (18\/20) were low grade. The most frequent dose\/fractionation scheme was 50 Gy in 25 fractions (16\/20), with 3 patients receiving 36 Gy in 18 fractions. Median pre-RT volume and greatest dimension were 120 cc (interquartile range [IQR]: 56\u2013399) and 11.2 cm (IQR: 8.4\u201314.1), respectively. Median percentage change in volume and greatest dimension were -37% (IQR: -57 to -29) and -10% (IQR: -20 to -7). All evaluable tumors decreased in volume during RT. Between pre- and post-RT MRI, most patients had a decrease in intratumoral (16\/20) and peritumoral edema (11\/20). Sixteen patients exhibited extensive pathologic response. There were no significant associations between radiographic and pathologic features and volumetric change. Local failure at 3 years was 9% (95% confidence interval: 1\u201359).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report significant decreases in MLPS tumor size during preoperative RT. There may be a role for adaptive RT planning to reduce target volumes and minimize RT-associated morbidity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2025-0032","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T14:18:04Z","timestamp":1750601884000},"page":"176-182","source":"Crossref","is-referenced-by-count":0,"title":["Radiographic and pathologic response of myxoid liposarcoma treated with preoperative radiotherapy"],"prefix":"10.2478","volume":"59","author":[{"given":"Robert W","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith AS","family":"Jebastin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris E","family":"Wenger","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, St SW , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S","family":"Harmsen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Information, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Folpe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Haddock","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy A","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester , Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia K","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Department of Radiation Oncology, Mayo Clinic , Phoenix , Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2026071215474201333_j_raon-2025-0032_ref_001","doi-asserted-by":"crossref","unstructured":"von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, et al. NCCN guidelines insights: Soft tissue sarcoma, Version 1.2021. J Natl Compr Canc Netw 2020; 18: 1604-12. doi: 10.6004\/jnccn.2020.0058.","DOI":"10.6004\/jnccn.2020.0058"},{"key":"2026071215474201333_j_raon-2025-0032_ref_002","doi-asserted-by":"crossref","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 1348-65. doi: 10.1016\/j.annonc.2021.07.006.","DOI":"10.1016\/j.annonc.2021.07.006"},{"key":"2026071215474201333_j_raon-2025-0032_ref_003","doi-asserted-by":"crossref","unstructured":"Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203. doi: 10.1200\/JCO.1998.16.1.197.","DOI":"10.1200\/JCO.1998.16.1.197"},{"key":"2026071215474201333_j_raon-2025-0032_ref_004","doi-asserted-by":"crossref","unstructured":"Harrison LB, Franzese F, Gaynor JJ, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 1993; 27: 259-65. doi: 10.1016\/0360-3016(93)90236-o.","DOI":"10.1016\/0360-3016(93)90236-O"},{"key":"2026071215474201333_j_raon-2025-0032_ref_005","doi-asserted-by":"crossref","unstructured":"Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14: 859-68. doi: 10.1200\/JCO.1996.14.3.859.","DOI":"10.1200\/JCO.1996.14.3.859"},{"key":"2026071215474201333_j_raon-2025-0032_ref_006","doi-asserted-by":"crossref","unstructured":"Davis AM, O\u2019Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005; 75: 48-53. doi: 10.1016\/j.radonc.2004.12.020.","DOI":"10.1016\/j.radonc.2004.12.020"},{"key":"2026071215474201333_j_raon-2025-0032_ref_007","doi-asserted-by":"crossref","unstructured":"Panwar U, Sankaye P. Preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma: A changing trend towards preoperative radiotherapy in the UK. Clin Oncol (R Coll Radiol) 2015; 27: 369-70. doi: 10.1016\/j.clon.2015.01.008.","DOI":"10.1016\/j.clon.2015.01.008"},{"key":"2026071215474201333_j_raon-2025-0032_ref_008","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359: 2235-41. doi: 10.1016\/S0140-6736(02)09292-9.","DOI":"10.1016\/S0140-6736(02)09292-9"},{"key":"2026071215474201333_j_raon-2025-0032_ref_009","doi-asserted-by":"crossref","unstructured":"Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol 2015; 33: 2231-8. doi: 10.1200\/JCO.2014.58.5828.","DOI":"10.1200\/JCO.2014.58.5828"},{"key":"2026071215474201333_j_raon-2025-0032_ref_010","doi-asserted-by":"crossref","unstructured":"Chung PW, Deheshi BM, Ferguson PC, Wunder JS, Griffin AM, Catton CN, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer 2009; 115: 3254-61. doi: 10.1002\/cncr.24375.","DOI":"10.1002\/cncr.24375"},{"key":"2026071215474201333_j_raon-2025-0032_ref_011","doi-asserted-by":"crossref","unstructured":"Engstr\u00f6m K, Bergh P, Cederlund CG, Hultborn R, Willen H, Aman P, et al. Irradiation of myxoid\/round cell liposarcoma induces volume reduction and lipoma-like morphology. Acta Oncol 2007; 46: 838-45. doi: 10.1080\/02841860601080415.","DOI":"10.1080\/02841860601080415"},{"key":"2026071215474201333_j_raon-2025-0032_ref_012","doi-asserted-by":"crossref","unstructured":"Lansu J, Bov\u00e9e JVMG, Braam P, van Boven H, Flucke U, Bonenkamp JJ, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. JAMA Oncol 2021; 7: e205865. doi: 10.1001\/jamaoncol.2020.5865.","DOI":"10.1001\/jamaoncol.2020.5865"},{"key":"2026071215474201333_j_raon-2025-0032_ref_013","doi-asserted-by":"crossref","unstructured":"Pitson G, Robinson P, Wilke D, Kandel RA, White L, Griffin AM, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys 2004; 60: 522-6. doi: 10.1016\/j.ijrobp.2004.03.009.","DOI":"10.1016\/j.ijrobp.2004.03.009"},{"key":"2026071215474201333_j_raon-2025-0032_ref_014","doi-asserted-by":"crossref","unstructured":"Betgen A, Haas RL, Sonke JJ. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol 2013; 2: 55-62. doi: 10.1007\/s13566-012-0085-0.","DOI":"10.1007\/s13566-012-0085-0"},{"key":"2026071215474201333_j_raon-2025-0032_ref_015","doi-asserted-by":"crossref","unstructured":"Gui C, Morris CD, Meyer CF, Levin AS, Frassica DA, Deville C, et al. Characterization and predictive value of volume changes of extremity and pelvis soft tissue sarcomas during radiation therapy prior to definitive wide excision. Radiat Oncol J 2019; 37: 117-26. doi: 10.3857\/roj.2018.00549.","DOI":"10.3857\/roj.2018.00549"},{"key":"2026071215474201333_j_raon-2025-0032_ref_016","doi-asserted-by":"crossref","unstructured":"Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 2010; 17: 2578-84. doi: 10.1245\/s10434-010-1156-3.","DOI":"10.1245\/s10434-010-1156-3"},{"key":"2026071215474201333_j_raon-2025-0032_ref_017","doi-asserted-by":"crossref","unstructured":"Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol 2010; 97: 404-7. doi: 10.1016\/j. radonc.2010.10.007.","DOI":"10.1016\/j.radonc.2010.10.007"},{"key":"2026071215474201333_j_raon-2025-0032_ref_018","doi-asserted-by":"crossref","unstructured":"Vakilian S, Freeman C, Al-Suhaibani A, Roberge D. Kinetics of myxoid liposar-coma radiation response and effects on radiation dose delivery. Pract Radiat Oncol 2013; 3: 180-5. doi: 10.1016\/j.prro.2012.06.005.","DOI":"10.1016\/j.prro.2012.06.005"},{"key":"2026071215474201333_j_raon-2025-0032_ref_019","doi-asserted-by":"crossref","unstructured":"Wortman JR, Tirumani SH, Tirumani H, Shinagare AB, Jagannathan JP, Hornick JL, et al. Neoadjuvant radiation in primary extremity liposarcoma: correlation of MRI features with histopathology. Eur Radiol 2016; 26: 1226-34. doi: 10.1007\/s00330-015-3953-3.","DOI":"10.1007\/s00330-015-3953-3"},{"key":"2026071215474201333_j_raon-2025-0032_ref_020","doi-asserted-by":"crossref","unstructured":"Houdek MT, Mallett KE, Heidenreich MJ, Ahmed SK, Wenger DE, Smith JH, et al. Lack of radiosensitivity predicts poor disease specific survival in myxoid liposarcoma. J Surg Oncol 2023; 127: 848-54. doi: 10.1002\/jso.27190.","DOI":"10.1002\/jso.27190"},{"key":"2026071215474201333_j_raon-2025-0032_ref_021","doi-asserted-by":"crossref","unstructured":"Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996; 77: 1450-8. doi: 10.1002\/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G.","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G"},{"key":"2026071215474201333_j_raon-2025-0032_ref_022","doi-asserted-by":"crossref","unstructured":"Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, et al. Myxoid\/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2007; 109: 2522-31. doi: 10.1002\/cncr.22720.","DOI":"10.1002\/cncr.22720"},{"key":"2026071215474201333_j_raon-2025-0032_ref_023","doi-asserted-by":"crossref","unstructured":"Muratori F, Bettini L, Frenos F, Mondanelli N, Greto D, Livi L, et al. Myxoid liposarcoma: Prognostic factors and metastatic pattern in a series of 148 patients treated at a single institution. Int J Surg Oncol 2018; 2018: 8928706. doi: 10.1155\/2018\/8928706.","DOI":"10.1155\/2018\/8928706"},{"key":"2026071215474201333_j_raon-2025-0032_ref_024","doi-asserted-by":"crossref","unstructured":"Lansu J, Van Houdt WJ, Schaapveld M, Walraven I, Van de Sande MAJ, Ho VKY, et al. Time trends and prognostic factors for overall survival in myxoid liposarcomas: a population-based study. Sarcoma 2020; 2020: 2437850. doi: 10.1155\/2020\/2437850.","DOI":"10.1155\/2020\/2437850"},{"key":"2026071215474201333_j_raon-2025-0032_ref_025","doi-asserted-by":"crossref","unstructured":"Haniball J, Sumathi VP, Kindblom LG, Abudu A, Carter SR, Tillman RM, et al. Prognostic factors and metastatic patterns in primary myxoid\/round-cell liposarcoma. Sarcoma 2011; 2011: 538085. doi: 10.1155\/2011\/538085.","DOI":"10.1155\/2011\/538085"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2025-0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:42:30Z","timestamp":1783903350000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2025-0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,6,1]]}},"alternative-id":["10.2478\/raon-2025-0032"],"URL":"https:\/\/doi.org\/10.2478\/raon-2025-0032","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}